公开(公告)号：EP2176223A1

公开(公告)日：2010-04-21

申请号：EP08773673.2

申请日：2008-06-26

申请人： Sanofi-Aventis

发明人： STEINHAGEN, Henning ,  SZILLAT, Hauke ,  FOLLMANN, Markus ,  KIRSCH, Reinhard ,  WEHNER, Volkmar ,  MATTER, Hans ,  LORENZ, Martin ,  NEUENSCHWANDER, Kent, W. ,  SCOTESE, Anthony, C.

IPC分类号： C07D213/30 ,  C07D213/80 ,  C07C15/00 ,  C07D211/42 ,  C07D213/34 ,  C07D309/08 ,  C07D409/12 ,  C07D413/12 ,  A61K31/44 ,  A61P7/00

CPC分类号： C07D213/80 ,  C07C257/18 ,  C07C311/08 ,  C07C311/46 ,  C07C317/22 ,  C07C317/32 ,  C07C2601/14 ,  C07D211/42 ,  C07D213/30 ,  C07D213/34 ,  C07D309/08 ,  C07D409/12 ,  C07D413/12

摘要： The present invention relates to compounds of the formula (I). The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIla and can in general be applied in conditions in which an undesired activity of factor VIla is present or for the cure or prevention of which an inhibition of factor VIla is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

摘要翻译： 本发明涉及式I化合物。式I化合物是有价值的药理活性化合物。 它们表现出强烈的抗血栓形成作用，并且适用于例如治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶，特别是因子VIIa的抑制剂，并且通常可以在其中存在不需要的因子VIIa的活性或用于治疗或预防因子VIIa的抑制的条件下使用。 本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。